Kymera Therapeutics (KYMR) Profit After Tax (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Profit After Tax for 8 consecutive years, with -$69.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 5.57% year-over-year to -$69.2 million; the TTM figure through Mar 2026 stood at -$316.8 million (down 33.56% YoY), while the FY2025 annual figure was -$311.4 million, down 39.08% from the prior year.
• Profit After Tax rose to -$69.2 million in Q1 2026 per KYMR's latest filing, from -$90.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$14.4 million in Q4 2023 and bottomed at -$90.0 million in Q4 2025.
• Historically, Profit After Tax has averaged -$52.8 million across 5 years, with a median of -$48.6 million in 2024.
• Annual changes were most pronounced in 2023 — Profit After Tax soared 51.48% — and 2024, when it tumbled 392.43%.
• Kymera Therapeutics' Profit After Tax stood at -$29.6 million in 2022, then jumped by 51.48% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then slipped by 27.16% to -$90.0 million in 2025, then advanced by 23.05% to -$69.2 million in 2026.
• Business Quant data shows KYMR's Profit After Tax at -$69.2 million in Q1 2026, -$90.0 million in Q4 2025, and -$81.0 million in Q3 2025.